Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00204633
Status:
COMPLETED
Last Update Posted:
2009-02-16
First Post:
2005-09-13
Brief Title:
Darbepoetin Alfa in Patients With Poor Prognosis Germ Cell Tumor Treated With High-Dose Chemotherapy HD-VIP
Sponsor:
University Hospital Tuebingen
Organization:
University Hospital Tuebingen
Study Overview
Official Title:
Randomized Phase II-Trial to Determine the Impact of Darbepoetin Alfa on the Frequency of RBC Transfusions in Patients With Metastatic Poor Prognosis Germ Cell Tumor Treated With High-Dose Chemotherapy HD-VIP Regimen
Status:
COMPLETED
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim is to determine the frequency of RBC transfusion in patients with metastatic poor prognosis germ cell tumor during high-dose chemotherapy HD-VIP level 6 with or without Darbepoetin alfa
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None